secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040238
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi reports $248.3M cash; hemophilia A program on track for IND in 2026
------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities $248.3M as of Dec 31, 2024; runway into 2027.
- FY2024 R&D expense $109.2M (up from $94.4M); G&A expense $32.0M (up from $28.8M).
- Hemophilia A program MGX-001: sustained FVIII activity in NHP >16 months; IND submission expected 2026.
- Ionis collaboration: four Wave 1 targets in lead optimization; plans to nominate 1-2 DCs in 2025.
- Board addition: Eric Bjerkholt (CFO of Mirum Pharmaceuticals) joins audit and compensation committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/0000950170-25-040238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025040238/mgx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer